Home › Companies › ZURA

Zura Bio

Market cap $99.7M 96.3M shares (10-Q, Oct 27, 2026) × $1.03 close Nov 17, 2026

Most recent annual filing: 2026-03-19

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Third indication undisclosed Ph2 startby year-end 2026Third indication undisclosed Ph2 start, by year-end 2026, routine
  2. Tibulizumab TibuSURE topline1H 2027Tibulizumab TibuSURE topline, 1H 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (1)

Capital (as filed)

Cash
$188M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$19K quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$188M cash, runway through at least the end of 2028 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Zura Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Zura Bio Limited (ZURA) - Scientific Deep Dive for Tibulizumab and Pipeline Products Legitimately de-risked financing and a real Q4 2026 binary keep this off the Pass pile, but the entire incremental thesis rides on the unproven BAFF arm, with governance/SPAC overhang and a stock already tripled off its lows — no clear edge in owning before HS data prints.
  2. Watch UPDATE: Zura Bio (ZURA) - The Third Shot on Goal Gets a Name PMR naming adds a setting where both IL-17 and BAFF arms have randomized clinical support, modestly narrowing the bear case, but the differentiating BAFF contribution in HS remains unproven and Q4 2026 remains a binary with the stock more than tripled off its lows.
  3. Avoid UPDATE: Zura Bio (ZURA) - The Placebo Ate the Readout TibuSHIELD missed every efficacy endpoint at both doses with no dose response, Zura is exiting HS, and the remaining value rests on an mRSS endpoint graveyard with a molecule whose tissue penetration is now in question and cash earmarked for burn rather than shareholders.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)